Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

银诺医药
INNOGEN

Guangzhou Innogen Pharmaceutical Group Co., Ltd.
廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

VOLUNTARY ANNOUNCEMENT
INTENTION TO CONDUCT ON-MARKET H SHARE REPURCHASE

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the "**Company**" together with its subsidiaries, the "**Group**") on a voluntary basis.

Reference is made to (i) the circular (the "**Circular**") of the Company dated 5 June 2026; and (ii) the poll results announcement (the "**Announcement**") of the Company dated 29 June 2026 in relation to, among others, the general mandate granted by the shareholders of the Company (the "**Shareholders**") to the board (the "**Board**") of directors (the "**Directors**") of the Company to repurchase not more than 10% of the H shares of the Company (the "**H Shares**") (excluding treasury shares) in issue as at the date of passing of the relevant resolution (the "**Repurchase Mandate**"). Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular and the Announcement.

The Board hereby announces that, during the period from 26 August 2026 up to the date of the next annual general meeting of the Company, it intends to exercise its powers under the Repurchase Mandate pursuant to the special resolution passed by the Shareholders at the AGM held on 29 June 2026 to repurchase H Shares by way of on-market transactions on the Main Board of the Stock Exchange with an intended aggregate amount of approximately HK$50,000,000 (the "**Intended H Share Repurchase**").

The Directors will exercise the power of the Company to make purchases pursuant to the Repurchase Mandate in accordance with the Listing Rules, the Articles of Association and the applicable laws, rules and regulations of the PRC. The Board currently has no intention to repurchase H Shares such that the obligation to make a mandatory offer under the Codes on Takeovers and Mergers and Share Buy-backs is triggered, and the Board will ensure that the Company continues to comply with the minimum public float requirement under the Listing Rules both before and after the Intended H Share Repurchase pursuant to the Repurchase Mandate.

The H Shares repurchased will be registered as treasury shares and are intended to be used for the share award scheme of the Company and/or to be cancelled directly in accordance with applicable laws, regulations and the Listing Rules.

The Board is of the view that conducting the Intended H Share Repurchase under the current circumstances demonstrates the Company's full confidence in its business outlook and prospects, and will ultimately benefit the Company and create value for Shareholders. The Board will apply funds from the Company's internal resources legally available for such purpose for the Intended H Share Repurchase. The Board is of the view that the Company's existing financial resources are sufficient to support the Intended H Share Repurchase while maintaining a sound financial position.

Shareholders and potential investors should note that any repurchase may be done subject to market conditions and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any repurchase. Shareholders and potential investors should therefore exercise caution when dealing in the Shares.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the PRC, 26 August 2026

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.